Nurix Therapeutics Reports Significant Q1 Revenue Decline and Widened Net Loss
NRIX sits 93% above its 52-week low of $8.18.
Summary
Nurix Therapeutics announced its first quarter 2026 financial results, reporting a substantial decrease in collaboration revenue and a wider net loss, despite ongoing progress in its clinical pipeline.
Key Events · Earnings and Guidance · NRIX
-
Q1 Revenue Miss
Collaboration revenue for the first quarter ended February 28, 2026, decreased significantly to $6.3 million, down from $18.5 million in the prior year period.
-
Widened Net Loss
The company reported a net loss of $87.2 million, or ($0.79) per share, for Q1 2026, compared to a net loss of $56.4 million, or ($0.67) per share, for Q1 2025.
-
Pipeline Advancement
Nurix highlighted ongoing enrollment in the DAYBreak CLL-201 pivotal Phase 2 study for bexobrutideg and plans to initiate a global randomized confirmatory Phase 3 trial by midyear 2026.
-
Strong Cash Position
The company ended the quarter with $540.7 million in cash, cash equivalents, and marketable securities.
Analysis · NRIX · Life Sciences
Nurix Therapeutics' Q1 2026 financial results show a significant decline in collaboration revenue and an increased net loss, indicating a challenging financial quarter. While the company highlighted continued advancement in its clinical programs, including ongoing enrollment in a pivotal Phase 2 study and plans for a Phase 3 trial for bexobrutideg, the substantial financial underperformance is a key concern for investors. The company's cash position remains strong at $540.7 million, providing runway for its clinical development, but the burn rate is notable. Investors will likely focus on the financial trajectory and the pace of clinical milestones to assess future value.
At the time of this filing, NRIX was trading at $15.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $8.18 to $22.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.